Potential Impact of Nutritional Intervention on End-Stage Renal Disease Hospitalization, Death, and Treatment Costs
|
|
- Kristopher Chase
- 6 years ago
- Views:
Transcription
1 ORIGINAL RESEARCH Potential Impact of Nutritional Intervention on End-Stage Renal Disease Hospitalization, Death, and Treatment Costs Eduardo Lacson, Jr., MD,* T. Alp Ikizler, MD, J. Michael Lazarus, MD,* Ming Teng, MD,* and Raymond M. Hakim, MD* Objective: Our objective was to estimate the effect of an improvement in nutrition, represented by albumin concentrations, on hospitalization, mortality, and Medicare end-stage renal disease (ESRD) program cost. Design: Based on published trials, the impact of an improvement in serum albumin of 0.2 g/dl from a hypothetical nutritional program for severely malnourished patients with albumin 3.5 g/dl (base case) was estimated by reassigning patients to higher albumin categories, along with outcome risks associated with the new albumin category. Setting: Data from Fresenius Medical Care North America (Waltham, MA) were utilized in regression models to determine the association between albumin and change in albumin concentration with outcomes. Results: Albumin 3.5 g/dl was associated with a 2-fold increase in death and hospitalization risk, compared to 4 g/dl (P.001) in this population. An increase in albumin concentration was associated with a lower risk of death and hospitalization, whereas a declining albumin concentration led to worse outcomes. Projections for the United States dialysis population from the base case showed 1400 lives saved, 6000 hospitalizations averted, and $36 million in Medicare cost savings resulting from a reduction of 20,000 hospital days. A sensitivity analysis, varying the albumin response to 0.1 and 0.3 g/dl combined with varying albumin responder rates to 25% and 75% of patients, revealed robust results. Conclusion: Nutritional interventions that increase serum albumin by 0.2 g/dl (e.g., via oral nutritional supplements) may lead to considerable improvements in mortality, hospitalization, and treatment costs by the National Kidney Foundation, Inc. NUTRITIONAL SUPPLEMENTATION, whether in the form of intradialytic parenteral nutrition (IDPN), 1-3 daily oral dietary assistance or supplementation, 4-6 or intradialytic oral nutrition (IDON), 7-9 increases the *Fresenius Medical Care North America, Waltham, Massachusetts. Nephrology Division, Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. Address reprint requests to Eduardo Lacson, Jr., MD, MPH, FASN, Vice President of Clinical Science, Epidemiology, and Research, Fresenius Medical Care North America, 920 Winter St., Waltham, MA elacsonj@fmc-na.com 2007 by the National Kidney Foundation, Inc /07/ $32.00/0 doi: /j.jrn albumin concentration in end-stage renal disease (ESRD) patients. These nutritional intervention studies indicate that serum albumin improves, on average, by 0.2 g/dl, ranging from 0.1 to 0.3 g/dl in the majority of patients. To our knowledge, a focused analysis that quantifies how graded improvements in serum albumin levels in patients with severe uremic wasting will influence hospitalization, death rates, and potential economic consequences is not available in the nephrology literature. We utilized the Fresenius Medical Care North America (Waltham, MA) database to estimate how nutritional improvement, indicated by increased serum albumin levels, may affect hospitalization, Journal of Renal Nutrition, Vol 17, No 6 (November), 2007: pp
2 364 LACSON ET AL mortality, and treatment costs for the United States (US) ESRD population. Methods The population examined includes 77,205 patients from the Fresenius Medical Care, North America (FMCNA) database with laboratory test results from October 1 to December 31, 2003 (fourth quarter, 2003) who survived into January 1, The case mix (age, gender, race, presence or absence of diabetes mellitus, and dialysis vintage), body surface area (BSA), and laboratory information (albumin, equilibrated Kt/V, hemoglobin, calcium, phosphorus, creatinine, and white blood cell count) were collected for analysis. Vascular access data were obtained for the hospitalization analyses. Demographic characteristics and laboratory profiles of the patient cohort and analytical subsets are presented as mean standard deviation or as percentages of the total. Dialysis vintage was defined as the number of days from the first maintenance dialysis on record, and was transformed into a square root in the analytical models for linearity. Follow-up information was tracked in the succeeding year, for hospitalizations, discharges (e.g., transplant, or transfer to another facility), and deaths from January 1 to December 31, The patient information was nationally distributed and comprised 26% of the US dialysis population in The analysis was conducted in three phases. Phase 1 examined associations between serum albumin and mortality risk, as well as hospitalization risk, consistent with previous studies The mean albumin concentration from the fourth quarter of 2003 for each of 77,205 patients was used in categorizing albumin (by increments of 0.1 g/dl) into ranges from 3.20 g/dl, 3.21 to 3.30 g/dl, and up to 4.00 g/dl. Three Cox proportional hazard models were constructed to determine mortality risk, by (1) using albumin as a single predictor variable, (2) adding case-mix (CM) variables to the albumin model, and then (3) adding laboratory (Lab) variables to model 2. The BSA was included in the final model under the CM Lab adjustment. For hospitalization, three logistic regression models were similarly constructed, except that creatinine and calcium were replaced by vascular access (VA) type as a predictor variable in the final model. Phase 2 utilized change in albumin concentration over an extended 1-year baseline period (2003) as an independent variable to determine an association with risk of hospitalization and death in 2004 for the subset of patients in the original Phase 1 cohort who were already on dialysis as of the first quarter of 2003, and who had a mean serum albumin of 3.5 g/dl. The change was defined as the difference from the mean serum albumin in the fourth quarter minus the mean serum albumin in the first quarter. Three models were created similar to that in Phase 1, with unadjusted, CM-adjusted, and CM Lab adjusted models to illustrate the associated mortality and hospitalization risk profiles. Phase 3 utilized a theoretical model on the basis of a hypothetical systematic nutritional intervention that increases serum albumin concentration for selected patients with severe malnutrition, defined (based on K/DOQI) as mean serum albumin concentration of 3.5 g/dl, 13 during the fourth quarter of Patients who respond are transferred from one albumin category to a higher albumin category, and the model assumes that the mortality and hospitalization risk for the higher category becomes applicable. We utilized crude (unadjusted) rates for both the hospitalization and mortality obtained from Phase 1 for each albumin category, at increments of 0.1 g/dl. In the base case, the projected increase of albumin concentration was an average of 0.2 g/dl for at least 50% of the intervention population. Therefore, 50% of the intervention patients from each albumin category ( 3.5 g/dl) were upgraded by 0.2 g/dl (e.g., from g/dl to g/dl, and from g/dl to g/dl) as depicted in Figure 1. The death risk associated with each albumin category was then applied to the projected (redistributed) patient population. A similar projection was utilized for hospitalization. The overall difference in death and hospitalization rates between the actual and projected number of patients in each serum albumin category represented the potential impact of the hypothetical intervention. The estimates were then extrapolated to the prevalent US dialysis population, assuming that the FMCNA population comprised a proportionately distributed national sample. The sensitivity analyses consisted of varying key assumptions along two dimensions: (1) net impact of the intervention on serum albumin, from 0.1 g/dl to 0.3
3 NUTRITIONAL INTERVENTION AND OUTCOMES IN ESRD 365 Figure 1. Projected distribution shift of the patient population resulting from a hypothetical systematic intervention with a 0.2 g/dl improvement in serum albumin in 50% of patients (base case). Only patients in albumin categories of 3.50 g/dl were projected to be reassigned to the higher albumin category, whereas the two categories between 3.51 and 3.70 g/dl were projected to receive some of those patients who improved. g/dl, and (2) change in prevalence of the improvement of albumin in patients with a baseline 3.5 g/dl to either 25% or 75%. Projected outcomes included mortality rate, lives saved, hospitalization events, and hospital days. For US hospitalization cost estimates, the projected counts of avoided hospital days were multiplied by the average Medicare cost of $1800 per hospital day. 14 The method used to derive this Medicare cost is in the Appendix. Statistical analyses were performed using SAS version 9.1 (SAS, Inc., Cary, NC). Results The patient characteristics for the mortality (N 77,205) and hospitalization (N 67,627) cohort populations in Phase 1 and Phase 2 (patient subset of Phase 1) are shown in Table 1. The mortality and hospitalization cohorts in each phase of the study were virtually identical in all aspects considered. In Phase 2 of the study, patients had a mean serum albumin of g/dl (first quarter), and the surviving cohort improved the population mean albumin to g/dl by the fourth quarter of By definition, these patients had to have survived from the first quarter into the fourth quarter of 2003, and thus patients who had serum albumins 3.5 g/dl from the first quarter of 2003 who failed to survive were excluded: hence the unavoidable selection bias toward patients whose albumins improved. However, the direction of such a bias in relation to outcomes would have been toward the null, because patients who died were more likely to have had lower albumin concentrations. Compared with the overall cohorts from Phase 1, the subset of patients in Phase 2 were older, more likely to be female, predominantly of white race, and more likely to be diabetic, and had a smaller BSA, less vintage, and a greater prevalence of patients with hemodialysis catheter access. The albumin-associated risk profiles from Phase 1 are shown in Figure 2. Albumin exhibited a robust association with both mortality and hospitalization risk. Albumin consistently maintained the strongest association with either outcome when compared with all other predictor variables included in any model (data not shown). Compared with patients with albumin 4.0 g/dl, patients with a mean serum albumin 3.5 g/dl exhibited an increased unadjusted risk for both mortality and hospitalization of approximately 3- to 5-fold (P.001). These risks were attenuated with CM Lab adjustment by an order of magnitude, down to 2- to 4-fold for both mortality and hospitalization (P.001). Phase 2 results are depicted in Figure 3, and confirm the association between a change in albumin concentration and risk of mortality and hospitalization. A decline in serum albumin concentration of 0.10 to 0.19 g/dl for severely malnourished patients increased the associated CM Lab-adjusted mortality risk by 9% (P.001), and by as much as 88% for a decline of 0.3 g/dl (P.001), as shown in Figure 3a. An increase in mean serum albumin concentration by 0.1 g/dl was associated with a significant 16% improved survival in the CM Lab-adjusted model (P.05), and by as much as a 30% improved survival with a 0.3 g/dl increase (P.001). In the hospitalization cohort, a decline of 0.3 g/dl had an associated increase in unadjusted hospitalization risk of 104% (P.001), attenuated in the fully adjusted models to 41% (P.05), as shown in Figure 3b. However, when albumin was increased by 0.2 g/dl, the associated hospitalization risk decreased by 25% for both unadjusted and fully adjusted models (range, 24% to 28%; P.05). Further, in patients whose albumin increased by
4 366 LACSON ET AL Table 1. Patient Characteristics for Mortality and Hospitalization Phase 1 (All Patients) and Phase 2 (Patient Subset With Mean Albumin 3.5 g/dl During the First Quarter of 2003) Patient Characteristics* Phase 1 Phase 2 Mortality Hospitalization Mortality Hospitalization Patient counts 77,205 67, Age (years) 61.4 (15.0) 61.6 (14.9) 63.3 (14.9) 63.3 (14.4) % female 47.0% 47.6% 54.1% 54.9% Race % white 49.2% 49.0% 52.2% 51.8% % black 40.8% 41.1% 38.1% 38.4% % other 10.0% 9.9% 9.7% 9.8% % with diabetes 51.9% 52.7% 63.8% 64.1% Vintage (days) Body surface area (m 2 ) 1.83 (0.27) 1.83 (0.27) 1.78 (0.26) 1.79 (0.26) Access type % with fistula 36% 36% 30% 30% % with graft 39% 40% 41% 41% % with catheter 23% 23% 28% 28% Albumin (g/dl) 3.87 (0.42) 3.87 (0.41) 3.54 (0.41) 3.55 (0.40) Equilibrated Kt/V 1.42 (0.29) 1.43 (0.28) 1.43 (0.29) 1.44 (0.28) Hemoglobin (g/dl) 11.8 (1.2) 11.8 (1.2) 11.8 (1.2) 11.8 (1.1) Calcium (mg/dl) 9.0 (0.8) 9.0 (0.8) 8.8 (0.7) 8.8 (0.7) Phosphorus (mg/dl) 5.3 (1.4) 5.3 (1.4) 5.3 (1.5) 5.3 (1.5) Creatinine (mg/dl) 9.5 (3.4) 9.5 (3.3) 8.4 (2.8) 8.4 (2.8) WBC count 7.2 (2.4) 7.2 (2.4) 7.3 (2.4) 7.3 (2.4) *Presented as mean (standard deviation) or percentage of the total where indicated, as of the end of the fourth quarter of Access type hemodialysis vascular access type, with a total of 100% because of missing data. WBC count white blood cell count, in units of 10 3 per microliter. 0.4 g/dl, the hospitalization risk declined by 41% (P.001). To our knowledge, there was no operative system-wide intervention to improve serum albumin in this subset of patients, except for general dietary recommendations. Among the 77,205 patients, there were 12,929 (17%) with a mean serum albumin 3.5 g/dl in the fourth quarter of 2003, meeting the definition of severe malnutrition, i.e., the target population for the hypothetical nutritional intervention. In the base case, if 50% of the target patients could improve serum albumin by 0.2 g/dl, the predicted overall death rate would decline by (an absolute) 0.48%, corresponding to 369 deaths averted. Similar base-case projections were made from the hospitalization information, to obtain an estimated possible 1646 hospitalizations averted and 5247 hospital days saved. The results are summarized in Table 2, with a sensitivity analysis on achieving the 0.2 g/dl improvement in serum albumin in only 25% as well as in 75% of target patients. The Phase 3 extrapolations of FMCNA projections for the US dialysis population are shown in Tables 3 to 6. A focused intervention that could improve albumin for all dialysis patients in the US with severe malnutrition could save 1400 lives per year, considering only the basecase scenario, i.e., 50% of severely malnourished patients improving their serum albumin by 0.2 g/dl. The sensitivity analysis in Table 3 shows that the projected number of lives saved, based on the achievable albumin improvement of 0.2 g/dl, is 712 lives for a modest 25% effect, 1419 lives for a likely 50% effect, and 2127 patients for a plausible 75% effect. Similarly, the projected number of possible lives saved for a 50% response to the intervention if the improvement in albumin is a modest 0.1 g/dl is 827 lives, while for 0.3 g/dl this increases to 1869 lives (with other combinations also shown in Table 3). The projected impact of the base case on hospitalization is a possible reduction by 6331 hospitalization events and 20,181 fewer hospital days. The sensitivity analyses are provided in Tables 4 and 5. Finally, the reduction in hospitalization was estimated to lead to a potential savings of $36 million in the base case, with a range from $14 million if only 25% of patients responded with an increase in serum albumin of 0.1 g/dl, to as high as $88 million if 75% of patients responded
5 NUTRITIONAL INTERVENTION AND OUTCOMES IN ESRD 367 Figure 2. Association between mean serum albumin level in the fourth quarter of 2003 with (a) mortality risk and (b) hospitalization risk during 2004, each shown with results from unadjusted, case-mix (CM)-adjusted, and fully adjusted models. with an improvement in serum albumin of 0.3 g/dl, as depicted in Table 6. Discussion This study confirms the strong association between albumin and change in albumin concentrations with outcomes. We further provide a model whereby small, realistic, but clinically feasible improvements in serum albumin were speculatively translated into significant numbers of lives saved, averted hospitalizations, and substantial cost savings. The current model allows for a graded change in albumin levels as well as the corresponding risks, without simply relying on all patients reaching a single threshold (e.g., all patients albumin 3.8 g/dl). 15 Furthermore, the model assumes a plausible response to the intervention, ranging from 25% to 75% of target patients with the base case at a 50% response, consistent with the low-end predicted response in another study. 16 The magnitude of albumin increase in the base case was 0.2 g/dl, achievable within the realm of published experience from a variety of nutritional interventions in ESRD. 1-9 Among enteral interventions, the effect on serum albumin was an average of 0.23 g/dl in a recent meta-analysis of 18 studies. 6 Our model indicates that an improvement in albumin of as little as 0.1 g/dl achieved in only 25% of severely malnourished (baseline serum albumin, 3.5 g/dl) ESRD patients in the US could still lead to 415 lives saved, 2165 hospitalizations averted, and approximately $15 million in potential annual cost savings, which is particularly strik-
6 368 LACSON ET AL Figure 3. Change in mean serum albumin level (first vs. fourth quarter of 2003) in the patient subset that started the first quarter of 2003 at a mean serum albumin of 3.5 g/dl, and the association with (a) mortality risk and (b) hospitalization risk during 2004, each shown with results from unadjusted, case-mix (CM)- adjusted, and fully adjusted models. Table 2. Projections of Possible Impact of a Systematic Intervention That Improves Albumin by 0.2 g/dl in 25% to 75% of Patients With a Baseline Serum Albumin 3.5 g/dl From the FMCNA Dialysis Population FMCNA Population, Possible Impact of Intervention % of Patients With Albumin 3.5 Improved by 0.2 g/dl 25% 50% 75% Number of hospitalization potential events avoided (%) 823 (0.80%) 1646 (1.59%) 2468 (2.59%) Potential hospital days avoided (%) 2624 (0.67%) 5247 (1.35%) 7871 (2.02%) Potential percentage decline in crude death rate 0.24% 0.48% 0.72% Potential lives saved FMCNA, Fresenius Medical Care, North America.
7 NUTRITIONAL INTERVENTION AND OUTCOMES IN ESRD 369 Table 3. Projections for the US ESRD Population Regarding Possible Lives Saved With an Intervention That Improves Nutritional Status in Patients With Serum Albumin 3.5 g/dl Possible Lives Saved Penetrance of Improvement in Albumin Improved Albumin From 3.5 g/dl 25% 50% 75% 0.1 g/dl , g/dl 712 1,419 2, g/dl 935 1,869 2,800 US ESRD, United States end-stage renal disease. Table 4. Projections for the US ESRD Population Regarding Possible Averted Hospitalizations With an Intervention That Improves Nutritional Status in Patients With Serum Albumin 3.5 g/dl Possible Averted Hospitalizations Penetrance of Improved Albumin Improvement in Albumin From 3.5 g/dl 25% 50% 75% 0.1 g/dl 2,165 4,831 6, g/dl 3,165 6,331 9, g/dl 4,815 9,865 14,450 US ESRD, United States end-stage renal disease. Table 5. Projections for the US ESRD Population Regarding Possible Reduction in Hospital Days With an Intervention That Improves Nutritional Status in Patients With Serum Albumin 3.5 g/dl Possible Reduction in Hospital Days Penetrance of Improved Albumin Improvement in Albumin from 3.5 g/dl 25% 50% 75% 0.1 g/dl 8,038 16,077 24, g/dl 10,092 20,181 30, g/dl 16,238 32,481 48,719 US ESRD, United States end-stage renal disease. ing considering that such an improvement is clearly achievable with available nutritional interventions. The most optimistic scenario, incorporating a mean increase of 0.3 g/dl in 75% of patients, projects potentially 2800 lives saved, 14,450 hospitalizations averted, and $88 million in potential annual cost savings. Optimal nutritional support in ESRD patients is not well-defined, and can be provided on several levels. Patient-related barriers include poor nutritional knowledge, poor appetite, lack of assistance with shopping and cooking, low fluid intake, acidosis, inadequate dialysis, depression, gastrointestinal symptoms, and difficulty chewing or swallowing. 17 In addition, the catabolic effect of comorbid conditions (e.g., infections) and of HD, postdialysis symptoms, missed opportunities for food intake as a result of preparations for dialysis, travel busy-ness as well as travel time to the dialysis unit, and the HD procedure itself, all combine to further exacerbate the imbalance between poor dietary intake and increased metabolic requirements Ease of monitoring makes interventions performed within HD units attractive, although such interventions are often limited to renal dieticians providing patients with nutritional information and dietary recommendations, with limited effectiveness. 4 Daily supplemental feeding is ideal and preferable, although patient compliance is difficult to achieve. Therefore, regular nutritional supplements administered within the dialysis unit, whether in the form of IDPN or IDON, provide an excellent supervised method to maximize patient compliance and monitor therapy. The high cost of IDPN therapy, a lack of adequately powered and designed clinical trials, and the regulatory concerns remain the greatest barriers to advocating for the utilization of this potentially beneficial treatment. Providing nutritional supplements during dialysis (i.e., IDON) is attractive, especially because feeding by mouth is more physiologic (described further below) and is an effective anabolic intervention in ESRD patients with functional gastrointestinal tracts. 6 Physiologic evidence supporting IDON includes findings that dietary intake during dialysis days is much lower when compared with nondialysis days. 21 Furthermore, evidence shows that the consumption of a protein- and energy-enriched meal during HD results in a positive protein balance, to the same extent as on a nondialysis day. 22 In addition, IDON induces a protein anabolic response comparable to IDPN in the acute setting if the protein and calorie content is similar, and promotes persistent anabolic benefits for muscle protein metabolism in the post-hd phase. 9 For example, a can each of Oxepa and Nepro taken together orally during each treatment in 20 malnourished patients (mean SD albumin, g/dl) increased albumin to g/dl (P.001) after 4 weeks. 23 Long-term, IDON over a 6-month period improved serum albumin ( g/dl to g/dl) and other nutritional parameters (e.g., serum prealbumin concentrations and subjective global assessment) in 85 malnourished patients. 8
8 370 LACSON ET AL Table 6. Projections for the US ESRD Population Regarding Potential Cost Savings From an Intervention That Improves Nutritional Status in Patients With Serum Albumin 3.5 g/dl Potential Cost Savings From Reduction of Hospitalization Penetrance of Improved Albumin Improvement in Albumin From 3.5 g/dl 25% 50% 75% 0.1 g/dl $14,469,231 $28,938,462 $43,400, g/dl $18,166,154 $36,325,385 $54,491, g/dl $29,229,231 $58,465,385 $87,694,615 US ESRD, United States end-stage renal disease. The present results should be interpreted with several caveats. First, serum albumin may be confounded by inflammation, fluid status, and a slow response to nutritional interventions. 13,24 However, albumin is an excellent marker of overall health status, correlates with other nutritional markers, responds to dietary intake, and is the most significant predictor of death and hospitalization risk ,25-27 In at least one recent randomized clinical trial, serum albumin was responsive to nutritional interventions irrespective of inflammatory markers. 17 A second limitation of this study is that the shift in serum albumin level from one category to another does not necessarily confer the improved risk profile for that particular category to a specific patient. Such causation can only be determined by a prospective, randomized clinical trial, e.g., despite numerous observational studies indicating improved outcomes with increasing dialysis dose beyond single pool Kt/V 1.2, the Hemodialysis Study was unable to demonstrate such a benefit. 28 In the absence of a definitive intervention study, we based our projections on available data, using epidemiologic tools. The analysis was conservative in projecting the change in risk by narrowing albumin categories while avoiding a blanket improvement in risk based on a single albumin threshold and excluding an unrealistic 100% patient response to the intervention. Thus, the methodology and results are conservative, believable, and plausible. Finally, the projections provided here are limited to patients with serum albumin 3.5 g/dl. It would be ideal to provide nutritional interventions for all patients who do not meet the target for serum albumin levels of 4.0 g/dl. However, the prevalence of patients with albumin 4.0 g/dl in the US is very high, considering that among patients entering the ESRD program in 2004 and 2005, the mean serum albumin concentration was 3.1 g/dl. 14 Therefore, a focused intervention for patients with severe malnutrition would be more affordable. In addition, the greatest risks, and potentially the greatest effect, should be associated with interventions directed toward patients with severe malnutrition, as noted in a prospective, randomized study where the intervention consisted of daily amino-acid supplements, and subjects with severe malnutrition ( 3.5 g/dl) had a greater improvement than those in the higher albumin strata of 3.5 to 3.8 g/dl (P.01). 7 In conclusion, we present projections based on data from our large database and a hypothetical focused nutritional intervention program. The analysis indicates that any nutritional intervention that can improve albumin by 0.2 g/dl (or higher) for patients with severe malnutrition may lead to improved outcomes, and appears to be cost-effective. Oral nutritional supplementation, at least during each hemodialysis procedure, is an effective and practical approach. A Medicare allowance for the provision of IDON may provide for an improvement in albumin levels that has been lacking since albumin was first tracked as a clinical performance measure. Alternatively, easing regulatory requirements on gifts for Medicare beneficiaries may make it possible for dialysis providers to fund a nutritional intervention program. A projected improvement in nutritional state, represented by biomarkers such as serum albumin, provides a reasonable likelihood for interventions to reduce death rates, hospitalization events, and ESRD-related costs. References 1. Chertow GM, Ling J, Lew NL, et al: The association of intradialytic parenteral nutrition administration with survival in hemodialysis patients. Am J Kidney Dis 24: , Capelli JP, Kushner H, Camiscioli TC, et al: Effect of intradialytic parenteral nutrition on mortality rates in end-stage renal disease care. Am J Kidney Dis 23: , Wong P, Smith P, Rodger D: The use of intradialytic parenteral nutrition to treat malnutrition: a case study. CANNT J 13:31-46, Wilson B, Fernandez-Madrid A, Hayes A, et al: Comparison of the effects of two early intervention strategies on the
9 NUTRITIONAL INTERVENTION AND OUTCOMES IN ESRD 371 health outcomes of malnourished hemodialysis patients. J Ren Nutr 11: , Hiroshige K, Sonta T, Suda T, et al: Oral supplementation of branched-chain amino acid improves nutritional status in elderly patients on chronic haemodialysis. Nephrol Dial Transplant 16: , Stratton RJ, Bircher G, Fouque D, et al: Multinutrient oral supplements and tube feeding in maintenance dialysis: a systematic review and meta-analysis. Am J Kidney Dis 46: , Eustace JA, Coresh J, Kutchey C, et al: Randomized double-blind trial of oral essential amino acids for dialysisassociated hypoalbuminemia. Kidney Int 57: , Caglar K, Fedje L, Dimmitt R, et al: Therapeutic effects of oral nutritional supplementation during hemodialysis. Kidney Int 62: , Pupim LB, Majchrzak KM, Flakoll PJ, et al: Intradialytic oral nutrition improves protein homeostasis in chronic hemodialysis patients with deranged nutritional status. J Am Soc Nephrol 17: , Lowrie EG, Lew NL: Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15: , Owen WF Jr, Lew NL, Liu Y, et al: The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 329: , Leavey SF, Strawderman RL, Jones CA, et al: Simple nutritional indicators as independent predictors of mortality in hemodialysis patients. Am J Kidney Dis 31: , National Kidney Foundation: Kidney Disease Outcomes Quality Initiative: Clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis 35(suppl): S1-S140, United States Renal Data System: Excerpts from the USRDS 2006 annual data report. Am J Kidney Dis 49(suppl): S1-S296, Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, et al: Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and populationattributable fraction. Nephrol Dial Transplant 20: , Port FK, Pisoni RL, Bragg-Gresham JL, et al: DOPPS estimates of patient life years attributable to modifiable hemodialysis practices in the United States. Blood Purif 22: , Leon JB, Albert JM, Gilchrist G, et al: Improving albumin levels among hemodialysis patients: a community-based randomized controlled trial. Am J Kidney Dis 48:28-36, Lindholm B, Wang T, Heimburger O, et al: Influence of different treatments and schedules on the factors conditioning the nutritional status in dialysis patients. Nephrol Dial Transplant 13(suppl 6):66-73, Ikizler TA, Pupim LB, Brouillette JR, et al: Hemodialysis stimulates muscle and whole body protein loss and alters substrate oxidation. Am J Physiol Endocrinol Metab 282:E107-E116, Kaysen GA, Kumar V: Inflammation in ESRD: causes and potential consequences. J Ren Nutr 13: , Burrowes JD, Larive B, Cockram DB, et al: Effects of dietary intake, appetite, and eating habits on dialysis and non-dialysis treatment days in hemodialysis patients: cross-sectional results from the HEMO Study. J Ren Nutr 13: , Veeneman JM, Kingma HA, Boer TS, et al: Protein intake during hemodialysis maintains a positive whole body protein balance in chronic hemodialysis patients. Am J Physiol Endocrinol Metab 284:E954-E965, Kalantar-Zadeh K, Braglia A, Chow J, et al: An antiinflammatory and antioxidant nutritional supplement for hypoalbuminemic hemodialysis patients: a pilot/feasibility study. J Ren Nutr 15: , Kaysen GA, Chertow GM, Adhikarla R, et al: Inflammation and dietary protein intake exert competing effects on serum albumin and creatinine in hemodialysis patients. Kidney Int 60: , Blumenkrantz MJ, Kopple JD, Gutman RA, et al: Methods for assessing nutritional status of patients with renal failure. Am J Clin Nutr 33: , Rocco MV, Soucie JM, Reboussin DM, et al: Risk factors for hospital utilization in chronic dialysis patients. Southeastern Kidney Council (Network 6). J Am Soc Nephrol 7: , Pupim LB, Evanson JA, Hakim RM, et al: The extent of uremic malnutrition at the time of initiation of maintenance hemodialysis is associated with subsequent hospitalization. J Ren Nutr 13: , Eknoyan G, Beck GJ, Cheung AK, et al: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347: , Appendix Computation of Average Medicare Cost for Each Hospital Day in Dialysis Patients (Source: United States Renal Data Systems [USRDS] 2006 Annual Data Report) Numerator: Inpatient Hospitalization Cost (Source: USRDS Table K.2) Total Inpatient Cost Transplant Cost Transplant Pass Through $6,699,571,501 $215,700,893 $4,964,072 Therefore: Inpatient Hospitalization Cost $6,478,906,534 Denominator: Total Hospital Days (Sources: USRDS Table G.6 and Subtable G.6.5) Total Hospital Days/Patient Year Total Years at Risk 14.1 Hospital Days/Patient-Year 249,176 Total Patient Years Therefore: Total Hospital Days 3,513,382 Hospital Days Computation: Medicare Average Cost per Hospital Day Inpatient Hospitalization Cost Total Hospital Days $6,478,906,534 3,513,382 Hospital Days Therefore: Medicare Average Cost per Hospital Day $1,844
End stage renal disease and Protein Energy wasting
End stage renal disease and Protein Energy wasting Dr Goh Heong Keong MBBS,MRCP(UK) www.passpaces.com/kidney.htm Introduction Chronic kidney disease- increasing health burden in many countries. The estimated
More informationTO EAT OR NOT TO EAT DURING HEMODIALYSIS TREATMENT?
TO EAT OR NOT TO EAT DURING HEMODIALYSIS TREATMENT? Rana G. Rizk, PhD, MPH, LD Maastricht University, The Netherlands November, 2017 Learning objectives Review the evidence behind benefits and concerns
More informationPrevalence of malnutrition in dialysis
ESPEN Congress Cannes 2003 Organised by the Israel Society for Clinical Nutrition Education and Clinical Practice Programme Session: Nutrition and the Kidney Malnutrition and Haemodialysis Doctor Noël
More informationIntradialytic Parenteral Nutrition. Description
Subject: Intradialytic Parenteral Nutrition Page: 1 of 9 Last Review Status/Date: September 2015 Intradialytic Parenteral Nutrition Description Intradialytic parenteral nutrition (IDPN) is the infusion
More informationIntradialytic Parenteral Nutrition
Intradialytic Parenteral Nutrition Policy Number: 8.01.44 Last Review: 8/2014 Origination: 8/2014 Next Review: 8/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for
More informationIntradialytic Parenteral Nutrition
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationIntradialytic Parenteral Nutrition
Intradialytic Parenteral Nutrition Policy Number: 8.01.44 Last Review: 8/2017 Origination: 8/2014 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for
More informationEffects of a Nationwide Predialysis Educational Program on Modality Choice, Vascular Access, and Patient Outcomes
Original Investigation Effects of a Nationwide Predialysis Educational Program on Modality Choice, Vascular Access, and Patient Outcomes Eduardo Lacson Jr, MD, MPH, Weiling Wang, MS, Cari DeVries, Keith
More information1. Reggie J. Divina, M.D. (1) 2. Fe S. Felicilda, M.D., DPBCN (1,2) 3. Rufino E. Chan, M.D. (1) 4. Luisito O. Llido, M.D.
82 TITLE: Nutritional status of hemodialysis patients in the Philippines: a cross sectional survey in four out- patient dialysis centers Submitted: January 10, 2010 Posted: August 30, 2010 AUTHOR(S) 1.
More informationIntradialytic Parenteral Nutrition in Hemodialysis Patients. Hamdy Amin, Pharm.D., MBA, BCNSP Riyadh, Saudi Arabia
Intradialytic Parenteral Nutrition in Hemodialysis Patients Hamdy Amin, Pharm.D., MBA, BCNSP Riyadh, Saudi Arabia Disclosure Information Intradialytic Parenteral Nutrition in Hemodialysis Patients Hamdy
More informationISN Mission: Advancing the diagnosis, treatment and prevention of kidney diseases in the developing and developed world
ISN Mission: Advancing the diagnosis, treatment and prevention of kidney diseases in the developing and developed world Nutrition in Kidney Disease: How to Apply Guidelines to Clinical Practice? T. Alp
More informationAspetti nutrizionali nel paziente in emodialisi cronica
Aspetti nutrizionali nel paziente in emodialisi cronica Enrico Fiaccadori enrico.fiaccadori@unipr.it Università degli Studi di Parma Agenda Diagnosis of protein-energy wasting (PEW) in ESRD on HD Epidemiology
More informationORIGINAL RESEARCH. 224 Journal of Renal Nutrition, Vol 20, No 4 (July), 2010: pp
ORIGINAL RESEARCH Independent and Joint Associations of Nutritional Status Indicators With Mortality Risk Among Chronic Hemodialysis Patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS)
More informationDialysis Dose and Body Mass Index Are Strongly Associated with Survival in Hemodialysis Patients
J Am Soc Nephrol 13: 1061 1066, 2002 Dialysis Dose and Body Mass Index Are Strongly Associated with Survival in Hemodialysis Patients FRIEDRICH K. PORT, VALARIE B. ASHBY, RAJNISH K. DHINGRA, ERIK C. ROYS,
More informationSrinivasan Beddhu 1,2*, Rebecca Filipowicz 2, Xiaorui Chen 2, Jill L Neilson 2, Guo Wei 2, Yufeng Huang 2 and Tom Greene 2
Beddhu et al. BMC Nephrology DOI 10.1186/s12882-015-0070-0 RESEARCH ARTICLE Open Access Supervised oral protein supplementation during dialysis in patients with elevated C-reactive protein levels: a two
More informationMalnutrition and inflammation in peritoneal dialysis patients
Kidney International, Vol. 64, Supplement 87 (2003), pp. S87 S91 Malnutrition and inflammation in peritoneal dialysis patients PAUL A. FEIN, NEAL MITTMAN, RAJDEEP GADH, JYOTIPRAKAS CHATTOPADHYAY, DANIEL
More informationEpidemiology, Diagnostic and treatment for Protein Energy Wasting in Dialysis
Epidemiology, Diagnostic and treatment for Protein Energy Wasting in Dialysis Pr Denis FOUQUE Department of Nephrology Centre de Recherche en Nutrition Humaine University Claude Bernard Lyon - France ESRD
More informationMacro- and Micronutrient Homeostasis in the Setting of Chronic Kidney Disease. T. Alp Ikizler, MD Vanderbilt University Medical Center
Macro- and Micronutrient Homeostasis in the Setting of Chronic Kidney Disease T. Alp Ikizler, MD Vanderbilt University Medical Center Nutrition and Chronic Kidney Disease What is the disease itself and
More informationThe mortality rate of treated patients with ESRD was 23
Early Intervention Improves Mortality and Hospitalization Rates in Incident Hemodialysis Patients: RightStart Program Rebecca L. Wingard,* Lara B. Pupim, Mahesh Krishnan, Ayumi Shintani, T. Alp Ikizler,
More informationTHE CURRENT PARADIGM of thrice-weekly
Dose of Dialysis: Key Lessons From Major Observational Studies and Clinical Trials Rajiv Saran, MD, MS, Bernard J. Canaud, MD, Thomas A. Depner, MD, Marcia L. Keen, PhD, Keith P. McCullough, MS, Mark R.
More informationDialysis Adequacy (HD) Guidelines
Dialysis Adequacy (HD) Guidelines Peter Kerr, Convenor (Monash, Victoria) Vlado Perkovic (Camperdown, New South Wales) Jim Petrie (Woolloongabba, Queensland) John Agar (Geelong, Victoria) Alex Disney (Woodville,
More informationNutrition in hemodialysis patients with focus on Intradialytic Parenteral Nutrition (IDPN)
Nutrition in hemodialysis patients with focus on Intradialytic Parenteral Nutrition (IDPN) Enrico Fiaccadori enrico.fiaccadori@unipr.it Acute and Chronic Renal Failure Unit Medicine & Surgery Dept. Parma
More informationTHE HEMODIALYSIS PRESCRIPTION: TREATMENT ADEQUACY GERALD SCHULMAN MD VANDERBILT UNIVERSITY MEDICAL SCHOOL NASHVILLE, TENNESSEE
THE HEMODIALYSIS PRESCRIPTION: TREATMENT ADEQUACY GERALD SCHULMAN MD VANDERBILT UNIVERSITY MEDICAL SCHOOL NASHVILLE, TENNESSEE THE DIALYSIS CYCLE /TIME DESIGN OF THE NATIONAL COOPERATIVE DIALYSIS STUDY
More informationPr Denis FOUQUE. Department of Nephrology Centre de Recherche en Nutrition Humaine University Claude Bernard Lyon - France
Pr Denis FOUQUE Department of Nephrology Centre de Recherche en Nutrition Humaine University Claude Bernard Lyon - France Observatoire Phosphocalcique, January 2011 1200 36.1 ± 5.0 g/l 1050 900 PEW
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Other criteria for starting dialysis GUIDELINES
Date written: September 2004 Final submission: February 2005 Other criteria for starting dialysis GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions
More information(1) DaVita Inc., Denver, CO; (2) DaVita Clinical Research, Minneapolis, MN
Oral Nutritional Supplement Provided During Dialysis is Not Superior to Dietary Counseling Provided by Registered Dietitians in Improving Serum Albumin Debbie Benner, MA, RD, CSR 1 ; Mary Burgess, MS,
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Blood urea sampling methods GUIDELINES
Date written: November 2004 Final submission: July 2005 Blood urea sampling methods GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions are
More informationDedicated outpatient vascular access center decreases hospitalization and missed outpatient dialysis treatments
http://www.kidney-international.org & 2006 International Society of Nephrology original article Dedicated outpatient vascular access center decreases hospitalization and missed outpatient dialysis treatments
More informationNutritional support in advanced kidney disease: Role of oral and parenteral nutrition. T. Alp Ikizler, MD Vanderbilt University Medical Center
Nutritional support in advanced kidney disease: Role of oral and parenteral nutrition T. Alp Ikizler, MD Vanderbilt University Medical Center Goals To delineate the mechanisms through which wasting syndrome
More informationLa relation dialyse et nutrition
Nutrition en dialyse : controverses La relation dialyse et nutrition Charles Chazot, MD NephroCare Tassin-Charcot Sainte Foy Les Lyon, France HEMO study lessons (1) Dose Body weight flux Rocco, Kidney
More informationNutrition and Renal Disease Update
Nutrition and Renal Disease Update Denis FOUQUE Department of Nephrology Centre de Recherche en Nutrition Humaine University Claude Bernard Lyon - France What have we learned? 1. Chronic kidney disease:
More informationRACE AND SEX DISPARITIES IN
ORIGINAL CONTRIBUTION Impact of Quality Improvement Efforts on Race and Sex Disparities in Hemodialysis Ashwini R. Sehgal, MD RACE AND SEX DISPARITIES IN health outcomes have been extensively documented.
More informationGender, low Kt/V, and mortality in Japanese hemodialysis patients: Opportunities for improvement through modifiable practices
Original Articles Gender, low Kt/V, and mortality in Japanese hemodialysis patients: Opportunities for improvement through modifiable practices Naoki KIMATA, 1 Angelo KARABOYAS, 2 Brian A. BIEBER, 2 Ronald
More informationEvaluation and management of nutrition in children
Evaluation and management of nutrition in children Date written: May 2004 Final submission: January 2005 Author: Elisabeth Hodson GUIDELINES No recommendations possible based on Level I or II evidence
More informationThe vexing problem of suboptimal initiation of dialysis: Can we do better?
Budapest Nephrology School August 30, 2010 The vexing problem of suboptimal initiation of dialysis: Can we do better? David C Mendelssohn Disclosures 2007 2010 Speaker Fees: Amgen, Ortho Biotech, Genzyme,
More informationNeed for specialized nutrition to prevent accelerated muscle loss in CKD
Need for specialized nutrition to prevent accelerated muscle loss in CKD Prof. Daniel Teta Head Service of Nephrology Hôpital du Valais, Sion CHUV, Université de Lausanne 21st September 2017 Conflicts
More informationChapter 5: Acute Kidney Injury
Chapter 5: Acute Kidney Injury Introduction In recent years, acute kidney injury (AKI) has gained increasing recognition as a major risk factor for the development of chronic kidney disease (CKD). The
More informationArtificial Nutritional Support in Chronic Hemodialysis Patients: A Narrative Review
REVIEW Artificial Nutritional Support in Chronic Hemodialysis Patients: A Narrative Review Maurizio Bossola, MD,* Luigi Tazza, MD,* Stefania Giungi, MD,* Fausto Rosa, MD, and Giovanna Luciani, MD* Objective:
More informationmean hemoglobin 11 g/dl (110 g/l) compared to patients with lower mean hemoglobin values (Table 20).
S44 Figure 53 depicts the trend in Epoetin dosing from the 1998 study period to the 2003 study period, with an increasing mean weekly Epoetin dose (units/kg/wk) for patients prescribed Epoetin in lower
More informationIn long-term hemodialysis (HD) patients, an arteriovenous
Change in Vascular Access and Hospitalization Risk in Long-Term Hemodialysis Patients Eduardo Lacson, Jr., Weiling Wang, J. Michael Lazarus, and Raymond M. Hakim Fresenius Medical Care, North America,
More informationRole of High-sensitivity C-reactive Protein as a Marker of Inflammation in Pre-dialysis Patients of Chronic Renal Failure
ORIGINAL ARTICLE JIACM 2009; 10(1 & 2): 18-22 Abstract Role of High-sensitivity C-reactive Protein as a Marker of Inflammation in Pre-dialysis Patients of Chronic Renal Failure N Nand*, HK Aggarwal**,
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Biochemical Targets. Calcium GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Biochemical Targets CARMEL HAWLEY (Woolloongabba, Queensland) GRAHAME ELDER (Westmead, New South Wales) Calcium GUIDELINES
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Serum phosphate GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Serum phosphate GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions
More informationNormal kidneys filter large amounts of organic
ORIGINAL ARTICLE - NEPHROLOGY Effect Of Lanthanum Carbonate vs Calcium Acetate As A Phosphate Binder In Stage 3-4 CKD- Treat To Goal Study K.S. Sajeev Kumar (1), M K Mohandas (1), Ramdas Pisharody (1),
More informationOriginal Article. Sean F. Leavey 2, Keith McCullough 1, Erwin Hecking 3, David Goodkin 4, Friedrich K. Port 2 and Eric W. Young 1,2.
Nephrol Dial Transplant (2001) 16: 2386 2394 Original Article Body mass index and mortality in healthier as compared with sicker haemodialysis patients: results from the Dialysis Outcomes and Practice
More informationEffects of Body Size and Body Composition on Survival in Hemodialysis Patients
J Am Soc Nephrol 14: 2366 2372, 2003 Effects of Body Size and Body Composition on Survival in Hemodialysis Patients SRINIVASAN BEDDHU,* LISA M. PAPPAS, NIRUPAMA RAMKUMAR, and MATTHEW SAMORE *Renal Section,
More informationCan Oral Supplementation with a Collagen-Casein-Based Liquid Protein Improve Serum Albumin Levels in Hemodialysis Patients?
Can Oral Supplementation with a Collagen-Casein-Based Liquid Protein Improve Serum Albumin Levels in Hemodialysis? Ann Pittaoulis, RD, LDN; Evelyn Phillips, MS, RD, LDN A. Pittaoulis is with Belmont Court
More informationQuestionnaire survey on nutritional supplement therapy and exercise training at hemodialysis facilities in Japan
Sakurai et al. Renal Replacement Therapy (2017) 3:60 DOI 10.1186/s41100-017-0137-4 RESEARCH Open Access Questionnaire survey on nutritional supplement therapy and exercise training at hemodialysis facilities
More informationNutrition Assessment in CKD
Nutrition Assessment in CKD Shiaw-Wen Chien, MD, EMBA Division of Nephrology, Department of Medicine, Tungs Taichung MetroHarbor Hospital Taichung, Taiwan September 10, 2017 Outline Introduction Composite
More informationMegestrol Acetate as a Treatment for Anorexia in Hemodialysis Patients
50 Journal of Nutritional Therapeutics, 2014, 3, 50-54 Megestrol Acetate as a Treatment for Anorexia in Hemodialysis Patients José L. Teruel *, Milagros Fernández-Lucas, Roberto Marcén, Antonio Gomis,
More informationHow is the dialysis patient different?
How is the dialysis patient different? Mihály Tapolyai, MD, FASN, FACP Fresenius Medical Care SOTE, Budapest; Hungary Minneapolis VAMC, Minneapolis, MN; USA How is the dialysis patient different? Dialysis
More informationImprovement in Pittsburgh Symptom Score Index After Initiation of Peritoneal Dialysis
Advances in Peritoneal Dialysis, Vol. 24, 2008 Matthew J. Novak, 1 Heena Sheth, 2 Filitsa H. Bender, 1 Linda Fried, 1,3 Beth Piraino 1 Improvement in Pittsburgh Symptom Score Index After Initiation of
More informationRCSIsmjoriginal article
The effect of optimising clinical performance measures on outcomes in haemodialysis patients Amy Bagatto 1, Nalayeni Errakiah 1, Mathan Munusamy 1, Rory McQuillan 2, Peter Conlon 2 1 RCSI medical student
More informationMEASURE INFORMATION FORM
MEASURE INFORMATION FORM Project Title: Comprehensive Reevaluation Dialysis Adequacy Project Overview: The Centers for Medicare & Medicaid Services (CMS) has contracted with the University of Michigan
More informationMortality for dialysis patients is highest during the
The Right of Passage: Surviving the First Year of Dialysis Rebecca L. Wingard, Kevin E. Chan, J. Michael Lazarus, and Raymond M. Hakim Fresenius Medical Care North America, Waltham, Massachusetts Mortality
More informationUSRDS UNITED STATES RENAL DATA SYSTEM
USRDS UNITED STATES RENAL DATA SYSTEM Chapter 10: Dialysis Providers In 2013, collectively the three large dialysis organizations treated 71% of patients in 67% of all dialysis units. In the Small Dialysis
More information"'\;;;;;;;;/ Fresenius Medical Care
~ "'\;;;;;;;;/ Internal Memo To: Medical Directors and Attending Physicians From: FMS Medical Office North America Corporate Headquarters Reseroir Woods 92 Winter St Waltham, MA 2451-1457 Date: Noember
More informationINTEGRATED CARE. Table 1. RVCARE core components and goals. Figure 2. Patients who choose PD in the RVCARE Program
The first 120 days of crucial care: Strategies for managing incident dialysis patients Naveena Reddy, MS, RD Farzeen Sukheswalla, MS, RD George R. Aronoff, MD, MS, FACP. The Renal ACO New Approaches to
More informationSince its first application as a treatment for end-stage
Dialysis Session Length ( t ) as a Determinant of the Adequacy of Dialysis Manjula Kurella and Glenn M. Chertow Several studies have shown an association between the hemodialysis session length (the t
More informationTo EAT or NOT to EAT At Treatment Debbie Benner, MA, RDN, CSR
To EAT or NOT to EAT At Treatment Debbie Benner, MA, RDN, CSR June 2016 Illinois Connection Ginny Pletzke Karen Graham EAT Co-authors: Brandon Kistler Kenneth Wilund Univ of Illinois, Champaign 2 Objectives
More informationSerum albumin concentration in dialysis patients: Why does it remain resistant to therapy?
Kidney International, Vol. 64, Supplement 87 (2003), pp. S92 S98 Serum albumin concentration in dialysis patients: Why does it remain resistant to therapy? GEORGE A. KAYSEN Department of Medicine, Division
More informationMalnutrition in advanced CKD
Malnutrition in advanced CKD Malnutrition Lack of proper nutrition, caused by not having enough to eat, not eating enough of the right things or being unable to use the food that one does eat Jessica Stevenson
More informationAre nutritional status indicators associated with mortality in the Hemodialysis (HEMO) Study?
Kidney International, Vol. 68 (2005), pp. 1766 1776 Are nutritional status indicators associated with mortality in the Hemodialysis (HEMO) Study? JOHANNA T. DWYER, BRETT LARIVE, JUNE LEUNG, MICHAEL V.
More informationKt/V underestimates the hemodialysis dose in women and small men
original article http://www.kidney-international.org & 8 International Society of Nephrology see commentary on page 262 Kt/V underestimates the hemodialysis dose in women and small men Elaine M. Spalding
More informationDOWNLOAD OR READ : NUTRITION DURING DIALYSIS TREATMENT PDF EBOOK EPUB MOBI
DOWNLOAD OR READ : NUTRITION DURING DIALYSIS TREATMENT PDF EBOOK EPUB MOBI Page 1 Page 2 nutrition during dialysis treatment nutrition during dialysis treatment pdf nutrition during dialysis treatment
More informationPreservation of Veins and Timing for Vascular Access
Preservation of Veins and Timing for Vascular Access Vassilis Liakopoulos, MD, PhD Department of Nephrology School of Medicine University of Thessaly Greece Hemodialysis VA A sound long-term dialysis access
More informationChapter 2: Identification and Care of Patients With CKD
Chapter 2: Identification and Care of Patients With Over half of patients from the Medicare 5% sample (restricted to age 65 and older) have a diagnosis of chronic kidney disease (), cardiovascular disease,
More informationChapter 2: Identification and Care of Patients With Chronic Kidney Disease
Chapter 2: Identification and Care of Patients With Chronic Kidney Disease Introduction The examination of care in patients with chronic kidney disease (CKD) is a significant challenge, as most large datasets
More informationPre-ESRD Changes in Body Weight and Survival in Nursing Home Residents Starting Dialysis
CJASN epress. Published on September 5, 2013 as doi: 10.2215/CJN.01410213 Article Pre-ESRD Changes in Body Weight and Survival in Nursing Home Residents Starting Dialysis Shobha Stack,* Glenn M. Chertow,*
More informationAdvances in Practice. Effect of Peridialytic Protein Bar Supplementation Among Malnourished Hemodialysis Patients
Advances in Practice Effect of Peridialytic Protein Bar Supplementation Among Malnourished Hemodialysis Patients Corresponding Author: Vasudevan Preethi MSc Clinical Nutrition Student, Department of Clinical
More information[1] Levy [3] (odds ratio) 5.5. mannitol. (renal dose) dopamine 1 µg/kg/min atrial natriuretic peptide (ANP)
[1] Levy [3] 183 174 (odds ratio) 5.5 Woodrow [1] 1956 1989 mannitol (renal dose) dopamine 1 µg/kg/min atrial natriuretic peptide (ANP) McCarthy [2] 1970 1990 insulin-like growth factor-1 (IGF-1) ANP 92
More informationThe Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009
The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 Teresa Northcutt, RN BSN Primaris Program Manager, Prevention - CKD MO-09-01-CKD This material was prepared by Primaris,
More informationQuarterly Dialysis Facility Compare - Preview for April 2018 Report DFC Dialysis Facility State: XX Network: 99 CCN: SAMPLE
Quarterly Dialysis Facility Compare -- Preview for April 2018 Report This Quarterly DFC Preview Report includes data specific to CCN(s): 999999 Purpose of the Report This report provides you with advance
More informationNutrition in end-stage renal disease
Kidney International, Vol. 50 (1996), pp. 343 357 PERSPECTIVES IN CLINICAL NEPHROLOGY Nutrition in end-stage renal disease Despite substantial improvements in the science and technology of renal replacement
More informationPneumonia in incident dialysis patients the United States Renal Data System
NDT Advance Access published November 19, 2007 Nephrol Dial Transplant (2007) 1 of 7 doi:10.1093/ndt/gfm474 Original Article Pneumonia in incident dialysis patients the United States Renal Data System
More informationChapter 2: Identification and Care of Patients With CKD
Chapter 2: Identification and Care of Patients With CKD Over half of patients in the Medicare 5% sample (aged 65 and older) had at least one of three diagnosed chronic conditions chronic kidney disease
More informationUSRDS UNITED STATES RENAL DATA SYSTEM
USRDS UNITED STATES RENAL DATA SYSTEM Chapter 2: Identification and Care of Patients With CKD Over half of patients from the Medicare 5 percent sample have either a diagnosis of chronic kidney disease
More informationOriginal Article. Introduction
Nephrol Dial Transplant (2004) 19: 100 107 DOI: 10.1093/ndt/gfg418 Original Article Haemodialysis prescription, adherence and nutritional indicators in five European countries: results from the Dialysis
More informationFINAL REPORT SEPTEMBER 2013
FINAL REPORT SEPTEMBER 2013 PREFACE In December 2008, Kidney Care Partners (KCP) took an unprecedented step to conduct a voluntary, national goal-based quality improvement initiative, and in January 2009
More informationMeasurement of dialyzer clearance, dialysis time, and body size: Death risk relationships among patients
Kidney International, Vol. 66 (24), pp. 277 284 Measurement of dialyzer clearance, dialysis time, and body size: Death risk relationships among patients EDMUND G. LOWRIE,ZHENSHENG LI,NORMA OFSTHUN, and
More informationLLL Session - Nutritional support in renal disease
ESPEN Congress Leipzig 2013 LLL Session - Nutritional support in renal disease Peritoneal dialysis D. Teta (CH) Nutrition Support in Patients undergoing Peritoneal Dialysis (PD) Congress ESPEN, Leipzig
More informationmorbidity & mortality
morbidity & mortality esrd introduction of ESRD treatment. We examine these concerns throughout the ADR, particularly in Chapter One. This year we focus on infectious complications, especially those related
More informationDESPITE MARKED ADVANCES in dialysis
ORIGINAL RESEARCH Predictive Value of Malnutrition Markers for Mortality in Peritoneal Dialysis Patients Cyntia Erthal Leinig, RD,* Thyago Moraes, MD, Sílvia Ribeiro, MD, PhD, Miguel Carlos Riella, MD,
More informationApplying clinical guidelines treating and managing CKD
Applying clinical guidelines treating and managing CKD Develop patient treatment plan according to level of severity. Source: Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012
More informationIN INDIVIDUALS WITH such chronic disease
Longitudinal Associations Between Dietary Protein Intake and Survival in Hemodialysis Patients Christian S. Shinaberger, MPH, Ryan D. Kilpatrick, MS, Deborah L. Regidor, MPH, Charles J. McAllister, MD,
More informationSurvival with Three-Times Weekly In-Center Nocturnal Versus Conventional Hemodialysis
Survival with Three-Times Weekly In-Center Nocturnal Versus Conventional Hemodialysis Eduardo Lacson Jr.,* Jianglin Xu,* Rita S. Suri, Gihad Nesrallah, Robert Lindsay, Amit X. Garg, Keith Lester,* Norma
More informationDialysis Initiation and Optimal Vascular Access: Outcomes and Mortality
Dialysis Initiation and Optimal Vascular Access: Outcomes and Mortality Shannon H. Norris, BSN, RN June 6, 2018 Dialysis Initiation and Optimal Vascular Access: Outcomes and Mortality DISCUSSION: End Stage
More informationJMSCR Vol. 03 Issue 07 Page July 2015
www.jmscr.igmpublication.org Impact Factor 3.79 ISSN (e)-2347-176x Inflammation and Its Association with Appetite and Quality of Life of Patients on Maintenance Hemodialysis Authors N. Vanitha Rani* 1,
More informationEffects of Diabetes Mellitus, Age, and Duration of Dialysis on Parathormone in Chronic Hemodialysis Patients. Hamid Nasri 1, Soleiman Kheiri 2
Saudi J Kidney Dis Transplant 2008;19(4):608-613 2008 Saudi Center for Organ Transplantation Saudi Journal of Kidney Diseases and Transplantation Original Article Effects of Diabetes Mellitus, Age, and
More informationHome Hemodialysis or Transplantation of the Treatment of Choice for Elderly?
Home Hemodialysis or Transplantation of the Treatment of Choice for Elderly? Miklos Z Molnar, MD, PhD, FEBTM, FERA, FASN Associate Professor of Medicine Division of Nephrology, Department of Medicine University
More informationThe use of surrogates as key performance indicators
REPLY The use of surrogates as key performance indicators Dr José Vinhas Department of Nephrology, Centro Hospitalar de Setúbal. Setúbal, Portugal Received for publication: 24/08/2012 Accepted: 31/08/2012
More information( ) , (Donabedian, 1980) We would not choose any treatment with poor outcomes
..., 2013 Amgen. 1 ? ( ), (Donabedian, 1980) We would not choose any treatment with poor outcomes 1. :, 2. ( ): 3. :.,,, 4. :, [Biomarkers Definitions Working Group, 2001]., (William M. Bennet, Nefrol
More informationPART ONE. Peritoneal Kinetics and Anatomy
PART ONE Peritoneal Kinetics and Anatomy Advances in Peritoneal Dialysis, Vol. 22, 2006 Paul A. Fein, Irfan Fazil, Muhammad A. Rafiq, Teresa Schloth, Betty Matza, Jyotiprakas Chattopadhyay, Morrell M.
More informationValidation of Mini Nutritional Assessment Scale in peritoneal dialysis patients
Clinical research Validation of Mini Nutritional Assessment Scale in peritoneal dialysis patients Szymon Brzosko 1, Tomasz Hryszko 1, Mariusz Kłopotowski 2, Michał Myśliwiec 1 1Department of Nephrology
More informationChapter 2: Identification and Care of Patients with CKD
Chapter 2: Identification and Care of Patients with CKD Over half of patients in the Medicare 5% sample (aged 65 and older) had at least one of three diagnosed chronic conditions chronic kidney disease
More informationSUBJECT INDEX. Tvedegaard, E., 20. Ulerich, L., E1 (July) Wapensky, T., 45 Warner, J., 116 Warsaba, D., 52
268 Supasyndh, O., 134 Suraci, C., 208 Tatangelo, P., 208 Tavares, I., 157 Tozzo, C., 208 Tvedegaard, E., 20 Ulerich, L., E1 (July) Wapensky, T., 45 Warner, J., 116 Warsaba, D., 52 Wells, L.M., 26 Winkler,
More informationEffect of Intradialytic Exercise on Echocardiographic Findings in Hemodialysis Patients
DIALYSIS Effect of Intradialytic Exercise on Echocardiographic Findings in Hemodialysis Patients Ali Momeni, 1 Alireza Nematolahi, 2 Mahsa Nasr 3 1 Division of Nephrology, Shahrekord University of 2 Department
More informationFull Title of Guideline: Author (include and role): Division & Speciality:
Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review date (when this version goes out of date): Explicit definition of patient
More informationChapter 5: Acute Kidney Injury
Chapter 5: Acute Kidney Injury In 2015, 4.3% of Medicare fee-for-service beneficiaries experienced a hospitalization complicated by Acute Kidney Injury (AKI); this appears to have plateaued since 2011
More informationSerum Albumin Level and Risk for Mortality and Hospitalization in Adolescents on Hemodialysis
Serum Albumin Level and Risk for Mortality and Hospitalization in Adolescents on Hemodialysis Sandra Amaral,* Wenke Hwang, Barbara Fivush, Alicia Neu, Diane Frankenfield, and Susan Furth *Department of
More information